集结号棋牌游戏下载

  • <tr id='jel4c'><strong id='jel4c'></strong><small id='jel4c'></small><button id='jel4c'></button><li id='jel4c'><noscript id='jel4c'><big id='jel4c'></big><dt id='jel4c'></dt></noscript></li></tr><ol id='jel4c'><option id='jel4c'><table id='jel4c'><blockquote id='jel4c'><tbody id='jel4c'></tbody></blockquote></table></option></ol><u id='jel4c'></u><kbd id='jel4c'><kbd id='jel4c'></kbd></kbd>

    <code id='jel4c'><strong id='jel4c'></strong></code>

    <fieldset id='jel4c'></fieldset>
          <span id='jel4c'></span>

              <ins id='jel4c'></ins>
              <acronym id='jel4c'><em id='jel4c'></em><td id='jel4c'><div id='jel4c'></div></td></acronym><address id='jel4c'><big id='jel4c'><big id='jel4c'></big><legend id='jel4c'></legend></big></address>

              <i id='jel4c'><div id='jel4c'><ins id='jel4c'></ins></div></i>
              <i id='jel4c'></i>
            1. <dl id='jel4c'></dl>
              1. <tr id='87gcz'><strong id='87gcz'></strong><small id='87gcz'></small><button id='87gcz'></button><li id='87gcz'><noscript id='87gcz'><big id='87gcz'></big><dt id='87gcz'></dt></noscript></li></tr><ol id='87gcz'><option id='87gcz'><table id='87gcz'><blockquote id='87gcz'><tbody id='87gcz'></tbody></blockquote></table></option></ol><u id='87gcz'></u><kbd id='87gcz'><kbd id='87gcz'></kbd></kbd>

                <code id='87gcz'><strong id='87gcz'></strong></code>

                <fieldset id='87gcz'></fieldset>
                      <span id='87gcz'></span>

                          <ins id='87gcz'></ins>
                          <acronym id='87gcz'><em id='87gcz'></em><td id='87gcz'><div id='87gcz'></div></td></acronym><address id='87gcz'><big id='87gcz'><big id='87gcz'></big><legend id='87gcz'></legend></big></address>

                          <i id='87gcz'><div id='87gcz'><ins id='87gcz'></ins></div></i>
                          <i id='87gcz'></i>
                        1. <dl id='87gcz'></dl>
                          1. <small id='yo93t'></small><noframes id='yo93t'>

                          2. <tfoot id='yo93t'></tfoot>

                              <legend id='yo93t'><style id='yo93t'><dir id='yo93t'><q id='yo93t'></q></dir></style></legend>
                              <i id='yo93t'><tr id='yo93t'><dt id='yo93t'><q id='yo93t'><span id='yo93t'><b id='yo93t'><form id='yo93t'><ins id='yo93t'></ins><ul id='yo93t'></ul><sub id='yo93t'></sub></form><legend id='yo93t'></legend><bdo id='yo93t'><pre id='yo93t'><center id='yo93t'></center></pre></bdo></b><th id='yo93t'></th></span></q></dt></tr></i><div id='yo93t'><tfoot id='yo93t'></tfoot><dl id='yo93t'><fieldset id='yo93t'></fieldset></dl></div>

                                  <bdo id='yo93t'></bdo><ul id='yo93t'></ul>

                                1. 您现在的位置: 共享健康网 >> 资讯 >> 特别推荐 >> 正文
                                  ESMO2019|新抗原疫苗-肺癌靶药耐药新突破
                                  文章作者:佚名 文章来源:健康网 更新时间:2019/9/29 15:11:41

                                  MUQIAN,2019OUZHOUZHONGLIUNEIKEXUEHUI(ESMO)NIANHUIZHENGZAIXIBANYABASAILUONEIZHAOKAI。ZAIBENCIDAHUISHANG,ZHONGLIUMIANYIZHILIAOCHENGGUOZHANSHIBEISHOUZHUMU。QIZHONGYIXIANGLAIZIZHONGGUOKEYANTUANDUIDEXINKANGYUANMIANYIZHILIAOLINCHUANGYANJIU,YINQILEGUONEIWAIZHUANJIAXUEZHEDEGUANGFANGUANZHU。ZHEIYESHIGAITUANDUISHOUCIGONGKAIQIYANJIUCHENGGUO。

                                  GAIYANJIUWEIGETIHUAXINKANGYUANYIMIAO(PPV)DUIDUOXIANZHILIAOSHIBAIHOUDEIII/IVQINSCLC IQILINCHUANGYANJIU,ZHUYAOYANJIUZHONGDIANSHIKEXINGXINGHEANQUANXING,CIYAOYANJIUZHONGDIANSHIPPVMIANYIYUANXING、WUJINZHANSHENGCUNQI(PFS)JIZONGSHENGCUNQI(OS)。

                                  TU1. XINKANGYUANZHONGLIUYIMIAOSHEJI、HECHENGJILINCHUANGZHILIAOLIUCHENG

                                  安全性良好

                                  GAITUANDUIDELINCHUANGYANJIUJIEGUOXIANSHI,24LIHUANZHEJIESHOUPPVZHILIAO,QIZHONG15LIHUANZHEDANCHUNJIESHOUPPVZHILIAO,9LIHUANZHEJIESHOUPPVYUEGFR-TKIDELIANHEZHILIAO。CHU3WEIHUANZHECHUXIANDUANZANPIZHEN、PIFAHUOFASHAOWAI,MEIYOUCHUXIANYUZHILIAOXIANGGUANDEYANZHONGHEZHIMINGDEBULIANGSHIJIAN,GENGMEIYOUHUANZHEYINWEIBULIANGSHIJIANERTINGZHIZHILIAO。QIE EGFRTUBIANXINGHUANZHEJIESHOU PPV ZHILIAOHUO PPV LIANHE EGFR-TKI ZHILIAOGUOCHENGZHONGMEIYOUCHUXIANBAOFAXINGJINZHANJIMIANYIXINGFEIYAN(PD-1/PD-L1 DANKANGZHILIAOCUNZAIGAILEIFENGXIAN)。

                                  DCR 67%,PPV与EGFR-TKI联用更有效

                                  24MINGHUANZHEJIESHOUPPVZHILIAO,QIZHONG1MINGHUANZHEWANQUANHUANJIE(CR),6MINGHUANZHEBUFENHUANJIE(PR),9MINGHUANZHEJIBINGWENDING(SD), JIBINGKONGZHILV(DCR)DADAO67%(16/24),YOUXIAOLVDA(ORR)DAO29%。ZHONGWEIPFSHEZHONGWEIOSFENBIEWEI6.0GEYUEHE8.9GEYUE。

                                  ZHIDEYITIDESHI,9LIHUANZHEEGFR-TKINAIYAOHOUZAIPPVZHILIAOTONGSHIJIXULIANHEEGFR-TKI,QISHENGCUNQIXIANGJIAO7LIPPVZHILIAOQIANYITINGFUEGFR-TKIDEHUANZHEMINGXIANYANZHANG(ZHONGWEIOS: 13.8 vs. 7.6GEYUE,P=0.038)。

                                  CHULINCHUANGSHUJUWAI,GAIYANJIUTUANDUIHAIDUIXINKANGYUANYIMIAOLIANHEEGFR-TKIZHILIAOJINXINGLESHENRUDEJIZHIYANJIU,XIANGGUANYANJIUSHUJUZAIESMO 2019HUIYISHANGYIPoster DiscussionJINXINGLETONGBUZHANSHI:

                                  激活免疫系统,PPV特异性T细胞增多

                                  GAIYANJIUJINYIBUDUIPPVZHILIAOQIANHOUBUTONGSHIJIANDIANCAIJIDEPBMC/ZUZHIYANGPINJINXINGLEELISA、ELISPOT、TetramerRANSE、MIANYIZUKUJIDANXIBAOMIANYIZUKUDENGXITONGXINGMIANYIJIANCE,YIZHENGMINGXINKANGYUANYIMIAOJUYOULIANGHAODEMIANYIYUANXINGBINGJIHUOLEHUANZHEJITIDEMIANYIXITONGSHASHANGZHONGLIU:JIANCHUDUOGEMIANYIYUANXINGXINKANGYUANBIAOWEI,QIZHONGFAXIAN2GEGAOGONGYOUXINGDEEGFRTUBIANZAIDUOMINGYINGDAHUANZHEPBMCZHONGJUNKEYINQIQIANGLIEMIANYIFANYING;PPVZHILIAO3GEYUEQIJIANPBMCZHONGXINKANGYUANTAITEYIXINGCD8+TXIBAOZHANBIZHUBUZENGJIA;PPVZHILIAOHOUPBMCHETILZHONGXINKANGYUANTAITEYIXINGCD8+TCRKELONGDEPINLVZENGJIA。

                                  EGFR-TKILIANHEMIANYIZHILIAOYOUWANGTUPONAIYAOPINGJING

                                  EGFRTUBIANXINGHUANZHEXIANGBIYESHENGXINGHUANZHE,PD-1/PD-L1DANKANGYAOWUDELIAOXIAOXIANGDUIJIAOCHA,ZHEIRANGYANJIUZHEMENDUIMIANYIZHILIAOYUEGFR-TKIDELIANYONGWANGERQUEBU。CICIXINKANGYUANYIMIAOLIANHEEGFR-TKIDEANQUANXINGYANJIU,ZAICIZHIQIANMEIYOUKEYICANKAODESHUJU,GAIZHONGCHANGSHIKEWEIDADANCHUANGXIN。QIEYANJIUJIEGUOBIAOMING,BULIANGSHIJIANFASHENGLVHEFANYINGJISHUDOUKONGZHIDEHENHAO。

                                  LINCHUANGYANJIUJIEGUOZHONG,JIESHOUXINKANGYUANYIMIAOLIANHEEGFR-TKIZHILIAODEHUANZHE,YUZHIJIESHOUXINKANGYUANYIMIAODANDUZHILIAODEHUANZHEXIANGBI,ZHONGWEISHENGCUNQIYANZHANGLE6.2GEYUE,CHUBUSHUOMINGLELIANHEZHILIAODEYOUSHI。JIEHE EGFR-TKI ZUOYONGYUZHONGLIUXIBAODEJIZHIYANJIU,KEYIFAXIAN EGFR-TKI DUIYUDIAOJIEZHONGLIUWEIHUANJINGJIJIECHUMIANYIYIZHIFAHUILEZHONGYAOZUOYONG。

                                  RANER,DUIYUGAILINCHUANGYANJIU,ZAISHENMEJIEDUANJIERUMIANYIZHILIAOZUIHESHI,MIANYIZHILIAOYU EGFR-TKI RUHEXIETONGYISHIXIANLINCHUANGHUOYIZUIDAHUADENGWEIZHIDELINGYU,HAIYOUDAIGENGSHENRUDITANSUO。

                                  GONGYOUXINGXINKANGYUANBIAOWEIZHUANHUAYIYIZHONGDA

                                  XINKANGYUANYIMIAOJUYOUHENQIANGDEZHONGLIUTEYIXING,KEYIYOUFAZHONGLIUTEYIXINGTXIBAOJIEDAOMIANYIFANYINGSHASHANGZHONGLIUXIBAO。MUQIANXINKANGYUANYIMIAOZHUYAOHAISHIZHENDUIBUTONGHUANZHEJINXINGDEGETIHUASHEJI,ZHEIQISHIYANZHONGXIANZHILEXINKANGYUANYIMIAODELINCHUANGYINGYONGXING。ERGONGYOUXINKANGYUANZAIMOUXIELEIXINGAIZHENGDEBUTONGHUANZHEJIANGONGTONGCUNZAI,MIANYIYUANXINGGAODEGONGYOUXINKANGYUANZEKEZHENDUIYOUXIANGTONGTUBIANJIYINWEIDIANDEHUANZHEYONGZUOZHILIAOXINGYIMIAO。

                                  CIXIANGYANJIUTIDAOFAXIANLEHOUXUANDEGONGYOUXINGXINKANGYUANBIAOWEI,2GEGAOGONGYOUXINGEGFRTUBIANDEXINKANGYUANZAIDUOMINGHUANZHEZHONGYOUMIANYIFANYING,JUYOUZHONGDADEZHUANHUAYIYI。

                                  ZAIZHILIAOXINGYIMIAODELINCHUANGYANJIULI,RUHETUPO「HUANZHENANHUOYI」ZHEIYIPINGJING,SHANGXUYEJIEDEGONGTONGNULI,TANSUOZHILURENGRANHENZHANG。

                                  JIZHEHUOXI,SHANGSHUYANJIUTUANDUIMUQIANZHENGZAIKAIZHANYIXIANGXINKANGYUANLINCHUANGYANJIU:GETIHUAXINKANGYUANTAIYIMIAODUISHITILIUDEIQILINCHUANGYANJIU(ChiCTR-IIR-17010557),QIDAIGAITUANDUIDAILAIGENGHAODEYANJIUCHENGGUO。

                                  CANKAOZILIAO

                                  [1] X. Du, F. Li, G. Lizee et al. Clinical study of personalized neoantigen peptide vaccination in advanced NSCLC patients. ESMO 2019. 1177PD

                                  [2] F. Li, G. Lizee, P. Hwu et al. The role of EGFR inhibitor (EGFRi) in immune cell infiltration and CD8+ T-cell activation in EGFR mutant lung cancer. ESMO 2019. 5PD

                                  文章录入:共享健康    责任编辑:gxjk  【发表评论
                                  网友评论:【发表评论】(只显示最新10条。评论内容只代表网友观点,与本站立场无关!)
                                  热门推荐
                                  热门图片文章

                                  没有任何图片文章

                                  百灵拼三张-Welcome 靠谱的棋牌---首页_Welcome 聚友棋牌官网下载安装-首页 蓝洞棋牌官网送3金币---首页_Welcome 035棋牌手游官网